NCT04089189 2026-01-28
SABRINA
Impact Therapeutics, Inc.
Phase 2 Completed
Clinical Trials
5 trialsNCT05390944 2025-09-16
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition
Impact Therapeutics, Inc.
Phase 1 Completed
NCT05391048 2025-09-16
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition
Impact Therapeutics, Inc.
Phase 1 Completed
NCT07030439 2025-06-22
A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State
Impact Therapeutics, Inc.
Phase 1 Completed
NCT07019194 2025-06-13
An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition
Impact Therapeutics, Inc.
Phase 1 Completed